Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure

Susheel Gundewar, John W. Calvert, Saurabh Jha, Iris Toedt-Pingel, Sang Yong Ji, Denise J. Nunez, Arun Ramachandran, Mauricio Anaya-Cisneros, Rong Tian, David J. Lefer

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Clinical studies have reported that the widely used antihyperglycemic drug metformin significantly reduces cardiac risk factors and improves clinical outcomes in patients with heart failure. The mechanisms by which metformin exerts these cardioprotective effects remain unclear and may be independent of antihyperglycemic effects. We tested the hypothesis that chronic activation of AMP-activated protein kinase (AMPK) with low-dose metformin exerts beneficial effects on cardiac function and survival in in vivo murine models of heart failure. Mice were subjected to permanent left coronary artery occlusion or to 60 minutes left coronary artery occlusion followed by reperfusion for 4 weeks. High-resolution, 2D echocardiography was performed at baseline and 4 weeks after myocardial infarction to assess left ventricular dimensions and function. Metformin (125 μg/kg) administered to mice at ischemia and then daily improved survival by 47% (P<0.05 versus vehicle) at 4 weeks following permanent left coronary artery occlusion. Additionally, metformin given at reperfusion and then daily preserved left ventricular dimensions and left ventricular ejection fraction (P<0.01 versus vehicle) at 4 weeks. The improvement in cardiac structure and function was associated with increases in AMPK and endothelial nitric oxide synthase (eNOS) phosphorylation, as well as increased peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α expression in cardiac myocytes. Furthermore, metformin significantly improved myocardial cell mitochondrial respiration and ATP synthesis compared to vehicle. The cardioprotective effects of metformin were ablated in mice lacking functional AMPK or eNOS. This study demonstrates that metformin significantly improves left ventricular function and survival via activation of AMPK and its downstream mediators, eNOS and PGC-1α, in a murine model of heart failure.

Original languageEnglish (US)
Pages (from-to)403-411
Number of pages9
JournalCirculation Research
Volume104
Issue number3
DOIs
StatePublished - Feb 13 2009
Externally publishedYes

Fingerprint

AMP-Activated Protein Kinases
Metformin
Left Ventricular Function
Heart Failure
Survival
Nitric Oxide Synthase Type III
Coronary Occlusion
Coronary Vessels
Hypoglycemic Agents
Reperfusion
Cell Respiration
Peroxisome Proliferator-Activated Receptors
Cardiac Myocytes
Stroke Volume
Echocardiography
Ischemia
Adenosine Triphosphate
Myocardial Infarction
Phosphorylation

Keywords

  • Heart failure
  • Metformin
  • Myocardial ischemia
  • Nitric oxide

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. / Gundewar, Susheel; Calvert, John W.; Jha, Saurabh; Toedt-Pingel, Iris; Ji, Sang Yong; Nunez, Denise J.; Ramachandran, Arun; Anaya-Cisneros, Mauricio; Tian, Rong; Lefer, David J.

In: Circulation Research, Vol. 104, No. 3, 13.02.2009, p. 403-411.

Research output: Contribution to journalArticle

Gundewar, S, Calvert, JW, Jha, S, Toedt-Pingel, I, Ji, SY, Nunez, DJ, Ramachandran, A, Anaya-Cisneros, M, Tian, R & Lefer, DJ 2009, 'Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure', Circulation Research, vol. 104, no. 3, pp. 403-411. https://doi.org/10.1161/CIRCRESAHA.108.190918
Gundewar, Susheel ; Calvert, John W. ; Jha, Saurabh ; Toedt-Pingel, Iris ; Ji, Sang Yong ; Nunez, Denise J. ; Ramachandran, Arun ; Anaya-Cisneros, Mauricio ; Tian, Rong ; Lefer, David J. / Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. In: Circulation Research. 2009 ; Vol. 104, No. 3. pp. 403-411.
@article{a03122373ff749598e63a9881ad8efd4,
title = "Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure",
abstract = "Clinical studies have reported that the widely used antihyperglycemic drug metformin significantly reduces cardiac risk factors and improves clinical outcomes in patients with heart failure. The mechanisms by which metformin exerts these cardioprotective effects remain unclear and may be independent of antihyperglycemic effects. We tested the hypothesis that chronic activation of AMP-activated protein kinase (AMPK) with low-dose metformin exerts beneficial effects on cardiac function and survival in in vivo murine models of heart failure. Mice were subjected to permanent left coronary artery occlusion or to 60 minutes left coronary artery occlusion followed by reperfusion for 4 weeks. High-resolution, 2D echocardiography was performed at baseline and 4 weeks after myocardial infarction to assess left ventricular dimensions and function. Metformin (125 μg/kg) administered to mice at ischemia and then daily improved survival by 47{\%} (P<0.05 versus vehicle) at 4 weeks following permanent left coronary artery occlusion. Additionally, metformin given at reperfusion and then daily preserved left ventricular dimensions and left ventricular ejection fraction (P<0.01 versus vehicle) at 4 weeks. The improvement in cardiac structure and function was associated with increases in AMPK and endothelial nitric oxide synthase (eNOS) phosphorylation, as well as increased peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α expression in cardiac myocytes. Furthermore, metformin significantly improved myocardial cell mitochondrial respiration and ATP synthesis compared to vehicle. The cardioprotective effects of metformin were ablated in mice lacking functional AMPK or eNOS. This study demonstrates that metformin significantly improves left ventricular function and survival via activation of AMPK and its downstream mediators, eNOS and PGC-1α, in a murine model of heart failure.",
keywords = "Heart failure, Metformin, Myocardial ischemia, Nitric oxide",
author = "Susheel Gundewar and Calvert, {John W.} and Saurabh Jha and Iris Toedt-Pingel and Ji, {Sang Yong} and Nunez, {Denise J.} and Arun Ramachandran and Mauricio Anaya-Cisneros and Rong Tian and Lefer, {David J.}",
year = "2009",
month = "2",
day = "13",
doi = "10.1161/CIRCRESAHA.108.190918",
language = "English (US)",
volume = "104",
pages = "403--411",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure

AU - Gundewar, Susheel

AU - Calvert, John W.

AU - Jha, Saurabh

AU - Toedt-Pingel, Iris

AU - Ji, Sang Yong

AU - Nunez, Denise J.

AU - Ramachandran, Arun

AU - Anaya-Cisneros, Mauricio

AU - Tian, Rong

AU - Lefer, David J.

PY - 2009/2/13

Y1 - 2009/2/13

N2 - Clinical studies have reported that the widely used antihyperglycemic drug metformin significantly reduces cardiac risk factors and improves clinical outcomes in patients with heart failure. The mechanisms by which metformin exerts these cardioprotective effects remain unclear and may be independent of antihyperglycemic effects. We tested the hypothesis that chronic activation of AMP-activated protein kinase (AMPK) with low-dose metformin exerts beneficial effects on cardiac function and survival in in vivo murine models of heart failure. Mice were subjected to permanent left coronary artery occlusion or to 60 minutes left coronary artery occlusion followed by reperfusion for 4 weeks. High-resolution, 2D echocardiography was performed at baseline and 4 weeks after myocardial infarction to assess left ventricular dimensions and function. Metformin (125 μg/kg) administered to mice at ischemia and then daily improved survival by 47% (P<0.05 versus vehicle) at 4 weeks following permanent left coronary artery occlusion. Additionally, metformin given at reperfusion and then daily preserved left ventricular dimensions and left ventricular ejection fraction (P<0.01 versus vehicle) at 4 weeks. The improvement in cardiac structure and function was associated with increases in AMPK and endothelial nitric oxide synthase (eNOS) phosphorylation, as well as increased peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α expression in cardiac myocytes. Furthermore, metformin significantly improved myocardial cell mitochondrial respiration and ATP synthesis compared to vehicle. The cardioprotective effects of metformin were ablated in mice lacking functional AMPK or eNOS. This study demonstrates that metformin significantly improves left ventricular function and survival via activation of AMPK and its downstream mediators, eNOS and PGC-1α, in a murine model of heart failure.

AB - Clinical studies have reported that the widely used antihyperglycemic drug metformin significantly reduces cardiac risk factors and improves clinical outcomes in patients with heart failure. The mechanisms by which metformin exerts these cardioprotective effects remain unclear and may be independent of antihyperglycemic effects. We tested the hypothesis that chronic activation of AMP-activated protein kinase (AMPK) with low-dose metformin exerts beneficial effects on cardiac function and survival in in vivo murine models of heart failure. Mice were subjected to permanent left coronary artery occlusion or to 60 minutes left coronary artery occlusion followed by reperfusion for 4 weeks. High-resolution, 2D echocardiography was performed at baseline and 4 weeks after myocardial infarction to assess left ventricular dimensions and function. Metformin (125 μg/kg) administered to mice at ischemia and then daily improved survival by 47% (P<0.05 versus vehicle) at 4 weeks following permanent left coronary artery occlusion. Additionally, metformin given at reperfusion and then daily preserved left ventricular dimensions and left ventricular ejection fraction (P<0.01 versus vehicle) at 4 weeks. The improvement in cardiac structure and function was associated with increases in AMPK and endothelial nitric oxide synthase (eNOS) phosphorylation, as well as increased peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α expression in cardiac myocytes. Furthermore, metformin significantly improved myocardial cell mitochondrial respiration and ATP synthesis compared to vehicle. The cardioprotective effects of metformin were ablated in mice lacking functional AMPK or eNOS. This study demonstrates that metformin significantly improves left ventricular function and survival via activation of AMPK and its downstream mediators, eNOS and PGC-1α, in a murine model of heart failure.

KW - Heart failure

KW - Metformin

KW - Myocardial ischemia

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=61949300140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61949300140&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.108.190918

DO - 10.1161/CIRCRESAHA.108.190918

M3 - Article

VL - 104

SP - 403

EP - 411

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 3

ER -